Biotech

All Articles

OS Treatments refiles $6M IPO to finance HER2 medication, preclinical ADCs

.OS Therapies will specify on the NYSE American supply exchange this morning by means of a $6.4 thou...

ALX's fizzling CD47 response cost delivers sell spiraling down

.ALX Oncology's phase 2 gastric cancer feedback price has diminished. After observing its CD47 block...

Ionis axes eye disease coming from targets of Roche-partnered prospect after records let down

.Yet Another of Ionis Pharmaceuticals' crucial midphase readouts has disappointed desires, motivatin...

Biogen's CEO mentioned no high-risk sell 2023. He's ready to be strong

.While Biogen's pharma peers are looking for late-stage properties along with little bit of risk, ch...

Instil refills pipe in $2B biobucks take care of ImmunOnco

.Instil Bio has actually been actually a biotech trying to find a pipe after it junked its lead asse...

Biogen ignores Denali Alzheimer's collab

.Biogen has actually returned liberties to an early Alzheimer's disease program to Denali Therapies,...

Takeda water faucets brand-new head people oncology service-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of considerable management hirings, firings...

Vertex, beaten by AATD once more, goes down 2 assets on throw away stack

.Vertex's effort to alleviate an uncommon genetic disease has reached one more trouble. The biotech ...

Vir increases 3 T-cell engagers from Sanofi, gives up 25% of workers

.Vir Medical's second-quarter earnings record wasn't short of major headlines. The company accepted ...

Galapagos pauses CAR-T cell therapy trial over Parkinsonism scenario

.Galapagos has paused enrollment in a trial of a BCMA-directed CAR-T cell treatment, pumping the bra...